SP
Therapeutic Areas
Breakthru Medicine Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lead Program (undisclosed) | Aggressive Solid Tumors | Pre-clinical |
Leadership Team at Breakthru Medicine
MM
Mark Mulvihill, PhD
Chief Science Officer
BB
Brian Barnett, MD
Chief Medical Officer
MG
Mark Gergen
Board Chair